Given the massive demand for more professional medical services in China, China's healthcare market is still on the rise. However, with the uprising challenges in data and legal aspects, how should French tech startups in health tech navigate this opportunity and succeed in China?
In Day 2 sessions, industry leaders, entrepreneurs & startup founders from health tech & the healthcare industry have come together in Shanghai to offer their valuable insights on the digital patient journey & pharmaceutical industry in China.
Olivier Dessajan, General Manager of Colisee China and Co-Chairman of the French Healthcare Alliance, started the day by saying a few words about the healthcare industry in China. Most notably, he mentioned the ageing society problem, the growing chronic disease, and the private sector’s innovation. He also briefing explained how the central government has placed healthcare in the centre of the country’s agenda by pushing the “Healthy China 2030” plan to support this industry in its way to catch up with the more developed countries.
Olivier Dessajan, General Manager of Colisee China and Co-Chairman of the French Healthcare Alliance
1 | MARKET INSIGHTS
Jens Ewert, the China Life Sciences and Health Care leader of Deloitte, took the audience through the trends, the transformation and concluded with some views they have at Deloitte about the outlook they have on China.
Jens Ewert concluded his keynote by advising the audience to keep in mind is that the healthcare innovation here in China is going on at the China speed and to enter with advanced technology that can overcome the firewalls in China. Moreover, the ecosystem in China is moving from a B2B model to a B2C model. And finally, smart disease management and care are becoming the new normal in China.
Jens Ewert, the China Life Sciences and Health Care leader of Deloitte
2 | DIGITAL PATIENT JOURNEY IN CHINA
It comes as no surprise that technology is notably embedded in China society today. Jens Ewert, the China Life Sciences and Health Care leader of Deloitte, Charles Bark, the Founder & CEO of HiNounou, Sebastien Gaudin, the Co-founder & CEO of The CareVoice, and Adam Tang, the Vice President of Qhealth Trusted doctors (Tencent) - shared in this session that China's digitalization in healthcare has proven to promote efficiency, satisfaction level of patients and healthcare providers, and cost reductions. The founders also shared, in detail, their best practices and experiences in raising funds for their health-tech startups in China.
Moderator - Jens Ewert, the China Life Sciences and Health Care leader of Deloitte
Sebastien Gaudin, the Co-founder & CEO of The CareVoice
Charles Bark, the Founder & CEO of HiNounou
Adam Tang, the Vice President of Qhealth Trusted doctors (Tencent)
4 | PHARMACEUTICAL INDUSTRY TRANSFORMATION
Benoit Raoult, Co-Founder & Managing Partner of Jumo Partners, Conni Ho, Executive Director at Run Young Capital Portfolio Management, Isabelle Doyon, Lawyer at DS Avocats, Luyan Liu, Business Development Manager at Lyvgen Biopharma, and Tom Robert, General Manager of Euris - discussed in this panel about the new "Personal Information Protection Law" that will take effect on 1st November 2021 in China. The panel speakers also reiterate the importance of partnership, as it helps foreign tech startups to grasp a better understanding of the digital ecosystem in China's pharmaceutical industry."
Based on Jumo’s methodology, the panel discussion followed the eight steps to enter the Chinese market:
IP
Regulatory
Clinical Trials
Importation
Distribution
Market Access
Promotion
Pharmacovigilance
Conni Ho, Executive Director at Run Young Capital Portfolio Management
Luyan Liu, Business Development Manager at Lyvgen Biopharma
Moderator - Benoit Raoult, Co-Founder & Managing Partner of Jumo Partners
Isabelle Doyon, Lawyer at DS Avocats
Tom Robert, General Manager of Euris
